InvestorNewsBreaks - Kairos Pharma, Ltd. (NYSE: KAPA) Receives 'Buy' Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report

Stock Information for Kairos Pharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kairos Pharma Ltd.

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Kairos Pharma Ltd. Provides Letter to Stockholders
Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer
Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105
Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.